• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结合靶向CXCR4和非靶向纳米颗粒用于有效的无辅助体外磁热疗。

Combining CXCR4-targeted and nontargeted nanoparticles for effective unassisted in vitro magnetic hyperthermia.

作者信息

Vilas-Boas Vânia, Espiña Begoña, Kolen'ko Yury V, Bañobre-Lopez Manuel, Duarte José A, Martins Verónica C, Petrovykh Dmitri Y, Freitas Paulo P, Carvalho Felix D

机构信息

UCIBIO-REQUIMTE, Laboratory of Toxicology, Biological Sciences Department, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal and International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga, 4715-330 Braga, Portugal.

International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga, 4715-330 Braga, Portugal.

出版信息

Biointerphases. 2018 Feb 5;13(1):011005. doi: 10.1116/1.5009989.

DOI:10.1116/1.5009989
PMID:29402091
Abstract

The use of targeted nanoparticles for magnetic hyperthermia (MHT) increases MHT selectivity, but often at the expense of its effectiveness. Consequently, targeted MHT is typically used in combination with other treatment modalities. This work describes an implementation of a highly effective monotherapeutic in vitro MHT treatment based on two populations of magnetic particles. Cells were sequentially incubated with two populations of magnetic particles: nonfunctionalized superparamagnetic nanoparticles and anti-CXCR4-functionalized particles. After removing the excess of free particles, an alternating magnetic field (AMF) was applied to produce MHT. The induced cytotoxicity was assessed at different time-points after AMF application. Complete loss of cell viability was observed 72 h after MHT when the iron loading of the anti-CXCR4-functionalized particles was boosted by that of a nontargeted population. Additionally, induction of necrosis resulted in more efficient cell death than did induction of apoptosis. Achieving a uniquely high effectiveness in monotherapeutic MHT demonstrates the potential of this approach to achieve complete loss of viability of cancer cells while avoiding the side effects of dual-treatment strategies that use MHT only as a sensitizing therapy.

摘要

使用靶向纳米颗粒进行磁热疗(MHT)可提高MHT的选择性,但往往会牺牲其有效性。因此,靶向MHT通常与其他治疗方式联合使用。这项工作描述了一种基于两种磁性颗粒群体的高效体外单药MHT治疗方法。细胞先后与两种磁性颗粒群体孵育:未功能化的超顺磁性纳米颗粒和抗CXCR4功能化颗粒。去除过量的游离颗粒后,施加交变磁场(AMF)以产生MHT。在施加AMF后的不同时间点评估诱导的细胞毒性。当抗CXCR4功能化颗粒的铁负载量由非靶向群体的铁负载量提高时,MHT后72小时观察到细胞活力完全丧失。此外,坏死诱导比凋亡诱导导致更有效的细胞死亡。在单药MHT中实现独特的高有效性证明了这种方法在实现癌细胞活力完全丧失的同时避免仅将MHT用作致敏疗法的联合治疗策略副作用的潜力。

相似文献

1
Combining CXCR4-targeted and nontargeted nanoparticles for effective unassisted in vitro magnetic hyperthermia.结合靶向CXCR4和非靶向纳米颗粒用于有效的无辅助体外磁热疗。
Biointerphases. 2018 Feb 5;13(1):011005. doi: 10.1116/1.5009989.
2
In vitro anti-cancer efficacy of multi-functionalized magnetite nanoparticles combining alternating magnetic hyperthermia in glioblastoma cancer cells.多功能化磁铁纳米粒子联合交变磁场热疗对神经胶质瘤细胞的体外抗癌疗效。
Mater Sci Eng C Mater Biol Appl. 2019 Aug;101:575-587. doi: 10.1016/j.msec.2019.04.007. Epub 2019 Apr 6.
3
Contribution of a 300 kHz alternating magnetic field on magnetic hyperthermia treatment of HepG2 cells.300千赫兹交变磁场对HepG2细胞磁热疗的作用
Bioelectromagnetics. 2013 Feb;34(2):95-103. doi: 10.1002/bem.21761. Epub 2012 Oct 11.
4
Comparative effects of magnetic and water-based hyperthermia treatments on human osteosarcoma cells.比较磁热疗和水热疗对人骨肉瘤细胞的影响。
Int J Nanomedicine. 2018 Sep 25;13:5743-5751. doi: 10.2147/IJN.S174853. eCollection 2018.
5
Hyperthermia generated by magnetic nanoparticles for effective treatment of disseminated peritoneal cancer in an orthotopic nude-mouse model.磁纳米颗粒产生的高热用于在原位裸鼠模型中有效治疗腹膜转移癌。
Cell Cycle. 2021 Jun;20(12):1122-1133. doi: 10.1080/15384101.2021.1919441. Epub 2021 Jun 10.
6
Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment.超顺磁性氧化铁纳米颗粒诱导的热疗在胶质瘤治疗中的应用。
Int J Nanomedicine. 2011;6:591-603. doi: 10.2147/IJN.S14737. Epub 2011 Mar 25.
7
Magnetic hyperthermia enhances cell toxicity with respect to exogenous heating.磁热疗相对于外源性加热增强细胞毒性。
Biomaterials. 2017 Jan;114:62-70. doi: 10.1016/j.biomaterials.2016.11.008. Epub 2016 Nov 9.
8
Iron Nanoparticles for Low-Power Local Magnetic Hyperthermia in Combination with Immune Checkpoint Blockade for Systemic Antitumor Therapy.铁纳米颗粒用于低功率局部磁热疗联合免疫检查点阻断的系统抗肿瘤治疗。
Nano Lett. 2019 Jul 10;19(7):4287-4296. doi: 10.1021/acs.nanolett.9b00579. Epub 2019 Jun 5.
9
Magnetic Hyperthermia for Cancer Treatment: Main Parameters Affecting the Outcome of In Vitro and In Vivo Studies.磁热疗治疗癌症:影响体外和体内研究结果的主要参数。
Molecules. 2020 Jun 22;25(12):2874. doi: 10.3390/molecules25122874.
10
Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer.用于磁热疗的磁性纳米颗粒和团簇:优化其热性能并开发联合疗法以攻克癌症。
Chem Soc Rev. 2021 Oct 18;50(20):11614-11667. doi: 10.1039/d1cs00427a.

引用本文的文献

1
Targeting the chemokine receptor CXCR4 for cancer therapies.以趋化因子受体CXCR4为靶点进行癌症治疗。
Biomark Res. 2025 May 1;13(1):68. doi: 10.1186/s40364-025-00778-y.
2
Advances in magnetic induction hyperthermia.磁感应热疗的进展
Front Bioeng Biotechnol. 2024 Aug 5;12:1432189. doi: 10.3389/fbioe.2024.1432189. eCollection 2024.
3
Influence of Coating and Size of Magnetic Nanoparticles on Cellular Uptake for In Vitro MRI.磁性纳米颗粒的涂层和尺寸对体外磁共振成像细胞摄取的影响
Nanomaterials (Basel). 2021 Oct 28;11(11):2888. doi: 10.3390/nano11112888.
4
Magnetic Hyperthermia for Cancer Treatment: Main Parameters Affecting the Outcome of In Vitro and In Vivo Studies.磁热疗治疗癌症:影响体外和体内研究结果的主要参数。
Molecules. 2020 Jun 22;25(12):2874. doi: 10.3390/molecules25122874.
5
Magnetogels: Prospects and Main Challenges in Biomedical Applications.磁凝胶:生物医学应用中的前景与主要挑战
Pharmaceutics. 2018 Sep 4;10(3):145. doi: 10.3390/pharmaceutics10030145.